奥曲肽及其类似物用于肿瘤治疗的进展  

Advances in tumor treatment with labeled somatostatin analogues

作　　者：马寄晓[1] 叶大铸 

机构地区：[1]上海交通大学附属第六人民医院核医学科 [2]Memorial Sloan-Kettering Cancer Center, New York 10021,USA

出　　处：《国外医学（放射医学核医学分册）》2005年第2期79-84,共6页Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)

摘　　要：简单综述90Y鄄奥曲肽、177Lu鄄奥曲肽在肿瘤治疗中的应用价值。对奥曲肽治疗的原理、在肿瘤及正常组织中的分布、对肾脏功能的影响和保护剂的应用进行介绍,主要治疗的病种包括不摄取131I的分化型甲状腺癌转移灶、Hurthle细胞甲状腺癌、甲状腺髓样癌、来自胃肠胰的神经内分泌肿瘤、小细胞癌、嗜铬细胞瘤等。对应用适合的剂量和未来新的可能用于临床治疗的放射肽和发展方向加以综述。The values of 90Y-octreotide and 177Lu-octreotate in tumor treatment were briefly reviewed.The rationale of clinincal applications, the distribution of radiopeptide in tumor and nomal tissues and appli-cation of renal protective agents were reviewed as well. Tumor with potential therapeutic responses are many such as non-iodide avid cancer of thyroid gland, Hurthle cell thyroid cancer, medullary thyroid cancer, neuroendo-gastro-entero-pancreatic(GEP)tumor, small cell l cancer, carcinoid tumors and pheochromocytoma. The current state of clinical use of radiopeptide for therapy of tumors, the development of new compounds and future development, the dosage of radiopeptide for tumor treatment with well tolerated and remarkable clinical benefit were presented.

关 键 词：生长抑素 奥曲肽 分化型甲状腺癌 Hurthle细胞甲状腺癌 甲状腺髓样癌:胃肠 胰神经内分泌肿瘤 小细胞癌 嗜铬细胞瘤 

分 类 号：R730.5[医药卫生—肿瘤]